The FDA has expanded the label for AstraZeneca’s oral PARP inhibitor olaparib to include the treatment of patients with metastatic breast cancer whose disease is associated with a BRCA gene mutation.
Researchers have discovered that anti-PD-1/PD-L1 therapies are highly effective in patients with desmoplastic melanoma, challenging previous assumptions.
Meta-analysis suggests long-term night shift work increases cancer risk amongst female workers, especially for nurses.
In this article from Future Oncology, the author considers the data supporting the sequential use of available EGFR TKIs and key considerations for selection of first-line treatment.
How do factors such as night work and light-at-night exposure increase a woman’s breast cancer risk? Find out in this editorial from Breast Cancer Management.